Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1 2Phase EARLY_PHASE1 1Phase 4 1Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 1

Interventions

Granulocyte-Macrophage Colony-Stimulating Factor 2trametinib 1naxitamab 1dabrafenib 1Itraconazole 1Isotretinoin 1Granulocyte Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Neuroblastoma × naxitamab × Clear all
NCT06047535 2023-09-21

Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.

SciClone Pharmaceuticals

Phase 4 Not yet recruiting
62 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡